BioSenic SA Logo

BioSenic SA

ISIN: BE0974280126 | Ticker: BIOS | LEI: 549300HFIIMTOP1DFR76
Sector: Health CareSub-Industry: Biotechnology
Country: Belgium

About BioSenic SA

Company Description

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.

Our expertise is focused on bone cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for bone and autoimmune and inflammatory diseases.

BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.

Year founded

2006

Served area

Worldwide

Headquarters

Bâtiment H (bte 24) Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Hainaut – Belgium

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Assets N/A 24,835,000.00 19,772,000.00
Noncurrent Assets N/A 6,019,000.00 5,481,000.00
Property Plant And Equipment N/A 226,000.00 863,000.00
Intangible Assets Other Than Goodwill N/A 28,000.00 24,000.00
Investments In Associates N/A 12,000.00 12,000.00
Noncurrent Receivables From Taxes Other Than Income Tax N/A 4,456,000.00 4,486,000.00
Other Noncurrent Assets N/A 1,296,000.00 96,000.00
Current Assets N/A 18,817,000.00 14,291,000.00
Trade And Other Current Receivables N/A 3,840,000.00 2,581,000.00
Cash and cash equivalents 8,633,000.00 14,648,000.00 9,510,000.00
Other Current Assets N/A 328,000.00 1,000,000.00
Equity And Liabilities N/A 24,835,000.00 19,772,000.00
Equity 2,048,000.00 3,325,000.00 -6,765,000.00
Issued Capital N/A 8,415,000.00 4,924,000.00
Retained Earnings N/A -73,080,000.00 -81,488,000.00
Share Premium N/A 67,594,000.00 69,499,000.00
Other Reserves N/A 396,000.00 301,000.00
Equity Attributable To Owners Of Parent N/A 3,325,000.00 -6,765,000.00
Noncontrolling Interests N/A 0.00 0.00
Liabilities N/A 21,510,000.00 26,537,000.00
Noncurrent Liabilities N/A 11,720,000.00 19,864,000.00
Other Noncurrent Liabilities N/A 0.00 112,000.00
Current Liabilities N/A 9,790,000.00 6,673,000.00
Trade And Other Current Payables To Trade Suppliers N/A 5,514,000.00 4,822,000.00
Current Tax Liabilities Current N/A 0.00 0.00
Other Current Liabilities N/A 1,199,000.00 804,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
Revenue 1,000,000.00 1,000,000.00
Revenue From Interest 24,000.00 25,000.00
Other Income 2,666,000.00 1,745,000.00
Profit Loss From Operating Activities -15,017,000.00 -12,026,000.00
Finance Income 0.00 333,000.00
Finance Costs 747,000.00 1,147,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method 0.00 0.00
Profit Loss Before Tax -15,754,000.00 -12,836,000.00
Income Tax Expense Continuing Operations 78,000.00 89,000.00
Profit Loss From Continuing Operations -15,832,000.00 -12,925,000.00
Profit Loss From Discontinued Operations 3,891,000.00 0.00
Profit Loss Attributable To Owners Of Parent -11,940,000.00 -12,925,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Adjustments For Sharebased Payments N/A 266,000.00 -99,000.00
Other Adjustments To Reconcile Profit Loss N/A -88,000.00 -65,000.00
Cash Flows From Used In Operations N/A -18,315,000.00 -14,565,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 78,000.00 89,000.00
Cash Flows From Used In Operating Activities N/A -16,082,000.00 -12,784,000.00
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 12,000,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 78,000.00 193,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 15,000.00 14,000.00
Interest Received Classified As Investing Activities N/A 2,000.00 3,000.00
Cash Flows From Used In Investing Activities N/A 11,908,000.00 -204,000.00
Payments From Changes In Ownership Interests In Subsidiaries N/A 1,956,000.00 0.00
Proceeds From Issuing Shares N/A 11,783,000.00 3,286,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 267,000.00 89,000.00
Interest Paid Classified As Financing Activities N/A 679,000.00 724,000.00
Cash Flows From Used In Financing Activities N/A 10,188,000.00 7,850,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 6,015,000.00 -5,138,000.00
Cash and cash equivalents 8,633,000.00 14,648,000.00 9,510,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
20.03.24 POMI SCHNEITER VERONIQUE Board Sell EUR 10,687.20
19.03.24 POMI SCHNEITER VERONIQUE Board Sell EUR 1,432.20
03.11.22 Stéphenne Jean Board Buy EUR 9,286.25
24.10.22 Pomi Véronique Board Buy EUR 0.00

Capital markets information

ISIN

BE0974280126

LEI

549300HFIIMTOP1DFR76

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Brussels

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.